Insightec’s Ultrasound technology opens Blood–Brain Barrier and enhances targeted drug delivery in Alzheimer’s disease

A study conducted at WVU Medicine shows that using a combination approach of Insightec’s focused ultrasound technology to open the blood-brain barrier with delivery of a systemic monoclonal antibody infusion, enhances the removal of cerebral beta-amyloid, a hallmark of Alzheimer’s disease.

The study, reported in the New England Journal of Medicine, included only three patients, but it raises hope about the long-term potential of the focused ultrasound treatment approach.

Alzheimer’s disease is a condition that affects 6.7 million Americans today. This breakthrough holds potential for improving targeted drug delivery in Alzheimer’s disease and other neurological conditions and opens up new avenues for research and provides renewed hope for patients and their loved ones.